Minrad has decided to move into a non-exclusive distributor arrangement with RxElite.
David DiGiacinto, president and COO of Minrad, said: “We had ongoing dialogue with the senior management of RxElite to assess and determine how to increase our joint penetration of anesthetic products in the US market.
“We believe this action will maximize the expertise of sales forces of both companies as well as the in-house support capabilities which RxElite has built to launch sevoflurane in the US human anesthetic market.”
Kirk Kamsler, Minrad’s senior vice president of commercial development, said: “We expect and will work towards ensuring that this ongoing change in selling strategy for our present and future anesthetics in the US market will be transparent to both the distribution customers and end users of this product.”